Osteoporosis Associated with Cancer Therapy

Heras-Herzig, Ailleen; Kozlow, Wende; Brown, Sue A.; Guise, Theresa A.

doi:10.1016/b978-012370544-0.50056-2

Cited by 2 publications

(1 citation statement)

References 275 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The introduction of LHRH agonists results in the achievement of castration levels of testosterone and a decrement in the estrogen levels [28]. Although the administration of the AR antagonists leads to an increase in the endogenous levels of both testosterone and estrogen, AR antagonist monotherapy results in a functional castration in men [29–31]. The current study shows that the SUA levels were significantly decreased after 6 months in both the LHRH and AR subgroups.…”

Section: Discussionmentioning

confidence: 67%

Influence of androgen deprivation therapy on serum urate levels in patients with prostate cancer: A retrospective observational study

Lee

Cho

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

ObjectivesAlthough estrogenic modulation of serum urate levels is well-known, the androgenic effect on urate homeostasis remains controversial. We investigated the effect of androgen deprivation therapy (ADT) on serum urate levels.MethodsWe retrospectively enrolled a total of 489 prostate cancer patients with available serum urate levels at baseline and 3 and 6 months after ADT (n = 150) or prostate surgery (n = 339). We extracted the demographic, clinical, and laboratory data from a data warehouse and compared the changes in urate levels between the two treatment groups and between the different ADT regimens (with versus without luteinizing hormone-releasing hormone (LHRH) agonists) using generalized estimating equation (GEE).ResultsThe baseline urate levels and the proportion of hyperuricemic subjects were comparable between the two groups. After 6 months, the urate levels were significantly decreased (by −0.66 mg/dL, 95% confidence interval (CI) [-0.81 to -0.51]) in the ADT group, whereas they did not significantly change in the surgery group in the univariate GEE analysis. The ADT group (4.7% from 18.0% at baseline) had a significantly lower proportion of hyperuricemic patients than surgery group (16.5% from 15.9% at baseline) at 6-month (p < 0.001). Regardless of whether LHRH agonists were used, the serial urate levels were lowered by the ADT. Temporal changes in the urate levels were significantly associated with the treatment group, baseline hyperuricemia, and poor functional or advanced cancer status. The ADT-related serum urate level reduction also remained significant in the multivariate GEE analysis (regression coefficient = −0.43 [−0.67 to −0.19] after 3 months and −0.37 [−0.64 to −0.10] after 6 months). Moreover, propensity-score-matched analyses yielded the same results.ConclusionsOur results showed that longitudinal serum urate levels were significantly reduced in men receiving ADT. This finding suggests that androgen could have an independent role in urate homeostasis.

show abstract

Section: Discussionmentioning

confidence: 67%